knowledge -WSS

knowledge

author：hotspot 2025-10-02 22:58:13 - browse：656

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Pancreatic cancer early detection could be helped by AI

WSS

5 dead in mass shooting on Caribbean island of St. Vincent: Police

The stock market has soared this year, but will it last? Experts weigh in

Syphilis numbers in the United States reach record heights

After a decade, new Gardasil ad campaign gets it (mostly) right

Telehealth startups are trying to fill the menopause care vacuum

Hormonal contraceptives don’t actually treat endometriosis

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Medical records are filled with copy

Reconstructing family trees of blood cells may help predict disease

At least 13 dead in Texas as scorching temps continue

Caribou posts encouraging results on off

United colonoscopy coverage change 'may cost lives,' doctors say

Philips to halt sales of sleep apnea machines in U.S.

How one medical school became remarkably diverse

Merck, Johnson & Johnson CEOs will testify on high drug prices

focus

After a decade, new Gardasil ad campaign gets it (mostly) right

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Scientists grapple with ethics of stem cell research

'CMA Fest' 2023: How to watch, who is performing and more

How a Boston hospital is priming medical residents to use GPT

White House pharmacy plagued with problems, investigation finds

hotspot

Wikipedia

focus

Wikipedia